+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
SYNCOMF

Syncom Formulation (India) Share Price

₹22.07 +0.66 (3.08%)
116.16% Gain from 52W Low

21 Oct, 2026 3:58 PM (IST)

Syncom Formulation (India) live price: ₹22.07. It opened at ₹22 vs previous close ₹21; intraday high/low: ₹22/₹21. The 50 & 200 DMA stand at ₹20.10/₹16.60.

Syncom Formulation (India) Performance

  • Today's Low
  • ₹21
  • Today's High
  • ₹22
  • 52 Week Low
  • ₹10
  • 52 Week High
  • ₹28
  • Open Price₹22
  • Previous Close₹21
  • Volume19,487,994
  • 50 DMA₹20.10
  • 100 DMA₹18.00
  • 200 DMA₹16.60

Syncom Formulation (India) Chart

Investment Returns

  • Over 1 Month + 11.18%
  • Over 3 Month + 62.64%
  • Over 6 Month + 61.68%
  • Over 1 Year + 31.6%

Smart Investing Starts Here Start SIP with Syncom Formulation (India) for Steady Growth!

Invest Now

Syncom Formulation (India) Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 24.3
  • PEG Ratio
  • 0.5
  • Market Cap Cr
  • 2,075
  • P/B Ratio
  • 4.7
  • Average True Range
  • 1.5
  • EPS
  • 0.9
  • Dividend Yield
  • 0.5
  • MACD Signal
  • 0.6
  • RSI
  • 52.43
  • MFI
  • 54.74

Latest Stock News Updates

Syncom Formulations India Ltd-$ - 524470 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate for Compliance of Regulation 74(5) of the SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended 30th September, 2026.

Syncom Formulations India Ltd-$ - 524470 - Announcement under Regulation 30 (LODR)-Dividend Updates

Corporate Announcement regarding approval and payment of final dividend.

Syncom Formulations India Ltd-$ - 524470 - Announcement under Regulation 30 (LODR)-Change in Management

Disclosure under reg 30 of SEBI (LODR) reg 2015 read with sub clause 7 of para A of part A of schedule /// change in directorate.

Syncom Formulation (India) Financials

Syncom Formulation (India) Technicals

EMA & SMA

Current Price
₹22.07
+ 0.66 (3.08%)
pointer
  • Bearish Moving Average 4
  • Bullish Moving Average 12
  • 20 Day
  • ₹22.00
  • 50 Day
  • ₹20.10
  • 100 Day
  • ₹18.00
  • 200 Day
  • ₹16.60

Resistance and Support

21.86 Pivot Speed
  • R3 23.60
  • R2 23.00
  • R1 22.50
  • S1 21.40
  • S2 20.70
  • S3 20.30

Syncom Formulation (India) Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-11 Quarterly Results, Final Dividend & A.G.M.
2026-05-22 Audited Results
2026-02-12 Quarterly Results
2025-11-12 Quarterly Results
2025-08-08 Quarterly Results & A.G.M.
Date Purpose Remarks
2026-09-23 FINAL Rs.0.10 per share(10%)Final Dividend
View Syncom Formulation (India) Dividend History Arrow
Date Purpose Remarks
2013-08-20 Split

Syncom Formulation (India) Shareholding Pattern

50.57%
47.2%
2.23%
0%

About Syncom Formulation (India)

Syncom Formulations (India) is geared up with latest production machineries and maintains high quality standards. Currently Syncom manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. View More
  • NSE Symbol
  • SYNCOMF
  • BSE Symbol
  • 524470
  • Managing Director,Chief Financial Officer
  • Rahul Vijay Bankda
  • ISIN
  • INE312C01025

Similar Stocks to Syncom Formulation (India)

Syncom Formulation (India) FAQs

Syncom Formulation (India) share price is ₹22 As on 22 October, 2026 | 07:25

The Market Cap of Syncom Formulation (India) is ₹2074.6 Cr As on 22 October, 2026 | 07:25

The P/E ratio of Syncom Formulation (India) is 24.3 As on 22 October, 2026 | 07:25

The PB ratio of Syncom Formulation (India) is 4.7 As on 22 October, 2026 | 07:25

The 52 week High & Low of Syncom Formulation (India) is ₹27.5/₹10.2 respectively As on 22 October, 2026 | 07:25

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23